156 related articles for article (PubMed ID: 25165412)
1. Effect of the Toll-like receptor 4 antagonist eritoran on retinochoroidal inflammatory damage in a rat model of endotoxin-induced inflammation.
Ekici F; Karaca EE; Korkmaz S; Yüksel O; Gülbahar Ö; Alper M; Ercan S; Or M
Mediators Inflamm; 2014; 2014():643525. PubMed ID: 25165412
[TBL] [Abstract][Full Text] [Related]
2. Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma.
Korff S; Loughran P; Cai C; Lee YS; Scott M; Billiar TR
J Surg Res; 2013 Oct; 184(2):e17-25. PubMed ID: 23777984
[TBL] [Abstract][Full Text] [Related]
3. In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia.
Ehrentraut S; Lohner R; Schwederski M; Ehrentraut H; Boehm O; Noga S; Langhoff P; Baumgarten G; Meyer R; Knuefermann P
Shock; 2011 Dec; 36(6):613-20. PubMed ID: 22089127
[TBL] [Abstract][Full Text] [Related]
4. Effects of eritoran tetrasodium, a toll-like receptor 4 antagonist, on intestinal microcirculation in endotoxemic rats.
Yeh YC; Ko WJ; Chan KC; Fan SZ; Tsai JC; Cheng YJ; Sun WZ
Shock; 2012 May; 37(5):556-61. PubMed ID: 22392144
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury.
Shimamoto A; Chong AJ; Yada M; Shomura S; Takayama H; Fleisig AJ; Agnew ML; Hampton CR; Rothnie CL; Spring DJ; Pohlman TH; Shimpo H; Verrier ED
Circulation; 2006 Jul; 114(1 Suppl):I270-4. PubMed ID: 16820585
[TBL] [Abstract][Full Text] [Related]
6. Decrease in the inflammatory cytokines of LPS-stimulated PBMCs of patients with atherosclerosis by a TLR-4 antagonist in the co-culture with HUVECs.
Talepoor AG; Rastegari B; Kalani M; Doroudchi M
Int Immunopharmacol; 2021 Dec; 101(Pt A):108295. PubMed ID: 34735917
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury.
Liu M; Gu M; Xu D; Lv Q; Zhang W; Wu Y
Transplant Proc; 2010 Jun; 42(5):1539-44. PubMed ID: 20620471
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling.
Mcdonald KA; Huang H; Tohme S; Loughran P; Ferrero K; Billiar T; Tsung A
Mol Med; 2015 Mar; 20(1):639-48. PubMed ID: 25375408
[TBL] [Abstract][Full Text] [Related]
9. The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy.
Ehrentraut H; Weber C; Ehrentraut S; Schwederski M; Boehm O; Knuefermann P; Meyer R; Baumgarten G
Eur J Heart Fail; 2011 Jun; 13(6):602-10. PubMed ID: 21613426
[TBL] [Abstract][Full Text] [Related]
10. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Opal SM; Laterre PF; Francois B; LaRosa SP; Angus DC; Mira JP; Wittebole X; Dugernier T; Perrotin D; Tidswell M; Jauregui L; Krell K; Pachl J; Takahashi T; Peckelsen C; Cordasco E; Chang CS; Oeyen S; Aikawa N; Maruyama T; Schein R; Kalil AC; Van Nuffelen M; Lynn M; Rossignol DP; Gogate J; Roberts MB; Wheeler JL; Vincent JL;
JAMA; 2013 Mar; 309(11):1154-62. PubMed ID: 23512062
[TBL] [Abstract][Full Text] [Related]
11. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
Barochia A; Solomon S; Cui X; Natanson C; Eichacker PQ
Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):479-94. PubMed ID: 21323610
[TBL] [Abstract][Full Text] [Related]
12. Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins.
Fleischer JG; Rossignol D; Francis GA; Chan T; Lynn M; Wasan KM
Innate Immun; 2012 Feb; 18(1):171-8. PubMed ID: 21382909
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of lipopolysaccharide-induced blood pressure attenuation and vascular contractility.
Ehrentraut S; Frede S; Stapel H; Mengden T; Grohé C; Fandrey J; Meyer R; Baumgarten G
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2170-6. PubMed ID: 17656666
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564).
Sun Y; Pearlman E
Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1247-54. PubMed ID: 18936141
[TBL] [Abstract][Full Text] [Related]
15. The TLR4 antagonist Eritoran protects mice from lethal influenza infection.
Shirey KA; Lai W; Scott AJ; Lipsky M; Mistry P; Pletneva LM; Karp CL; McAlees J; Gioannini TL; Weiss J; Chen WH; Ernst RK; Rossignol DP; Gusovsky F; Blanco JC; Vogel SN
Nature; 2013 May; 497(7450):498-502. PubMed ID: 23636320
[TBL] [Abstract][Full Text] [Related]
16. Myeloid differentiation 2 as a therapeutic target of inflammatory disorders.
Park SH; Kim ND; Jung JK; Lee CK; Han SB; Kim Y
Pharmacol Ther; 2012 Mar; 133(3):291-8. PubMed ID: 22119168
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.
Tidswell M; LaRosa SP
Expert Rev Anti Infect Ther; 2011 May; 9(5):507-20. PubMed ID: 21609262
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 4/nuclear factor-kappa B pathway is involved in myocardial injury in a rat chronic stress model.
Wang RP; Yao Q; Xiao YB; Zhu SB; Yang L; Feng JM; Li DZ; Li XL; Wu JJ; Chen J
Stress; 2011 Sep; 14(5):567-75. PubMed ID: 21675862
[TBL] [Abstract][Full Text] [Related]
19. Investigation of protective effects of apilarnil against lipopolysaccharide induced liver injury in rats via TLR 4/ HMGB-1/ NF-κB pathway.
Doğanyiğit Z; Okan A; Kaymak E; Pandır D; Silici S
Biomed Pharmacother; 2020 May; 125():109967. PubMed ID: 32018220
[TBL] [Abstract][Full Text] [Related]
20. Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats.
Kitazawa T; Tsujimoto T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2010 May; 25(5):1009-12. PubMed ID: 20546456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
